Search

Displaying results 3121 - 3130 of 10000 in total
  1. Drug

    Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB10779
    ApprovedInvestigational

    Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus … Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3.

    Mixtures: Fluarix Tetra Injektionssuspension in einer Fertigspritze
  2. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [A260207] AChR is vital for signal transduction in the neuromuscular junctions (NMJ) by generating muscle end plate potentials to propagate action potential. … [A260177] It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia gravis.

  3. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    for the treatment of relapsed or refractory DLBCL in adult patients who cannot receive autologous stem cell transplants. … Tafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies.

  4. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    [L3344] On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.

  5. Drug

    Phenyl salicylate

    go.drugbank.com/drugs/DB11071
    Approved

    It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in [DB00945] ). … Phenyl salicylate is used as a food additive in the USA [L2479]. This compound belongs to the class of organic compounds known as depsides and depsidones.

    Mixtures: UR N-C Urinary Antiseptic
  6. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  7. Drug

    Bosentan

    go.drugbank.com/drugs/DB00559
    ApprovedInvestigational

    Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. … Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals.

    Categories: Antihypertensives for Pulmonary Arterial HypertensionSynonyms: p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide, 4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
  8. Drug

    Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)

    go.drugbank.com/drugs/DB10991
    ApprovedInvestigational

    Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus

    Mixtures: Hexaxim Suspension for Injection, BOOSTRIX POLIO SUSPENSION FOR INJECTION
  9. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    [L2502] Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018. … [L2502] Sinapultide is a 21-residue peptide made up of lysine (K) and leucine (L) residues with the sequence KLLLLKLLLLKLLLLKLLLLK (KL4), in aqueous dispersion with the phospholipids DPPC (dipalmitoylphosphatidylcholine

  10. Drug

    Ethambutol

    go.drugbank.com/drugs/DB00330
    ApprovedInvestigational

    [L31743] Ethambutol was first described in the literature in 1961.[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_. … [A229048] Ethambutol was granted FDA approval on 6 November 1967.[L31663]

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisSynonyms: (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine